Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Hannah Ray

Nurse Practitioner Huntsville, AL Nurse Practitioner

NPI 1366171514 CMS profile 11347169

2045 Cecil Ashburn Dr Se Ste 201, Huntsville, AL 35802

Open in the dashboard

General payments

$3,295

146 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Ray of Huntsville, AL is reported in the CMS Open Payments database as having received $3,295 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,468 75
2024 General $1,070 41
2023 General $608 22
2022 General $149 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Ray
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Hannah Ray were reported at $1,468. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Hannah Ray Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $149 $152 $48–$470 $149
2023 $608 $166 $54–$529 $160
2024 $1,070 $173 $55–$556 $164
2025 $1,468 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novartis Pharmaceuticals Corporation $486 30 payments
  2. Sun Pharmaceutical Industries Inc. $352 11 payments
  3. AbbVie, Inc. $338 19 payments
  4. Galderma Laboratories, L.P. $298 24 payments
  5. LEO Pharma Inc. $292 7 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $262 11 payments
  7. E.R. Squibb & Sons, L.L.C. $199 9 payments
  8. Amgen Inc. $180 5 payments
  9. Genzyme Corporation $167 5 payments
  10. Paratek Pharmaceuticals, Inc. $159 3 payments
  11. Other $562 22 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,111 143 payments
  2. Education $184 3 payments
Products named General payments · program years 2022–2025
  1. COSENTYX $271 23 payments
  2. SILIQ $262 11 payments
  3. NEMLUVIO $235 21 payments
  4. ILUMYA $211 9 payments
  5. SKYRIZI $203 12 payments
  6. Otezla $180 5 payments
  7. DUPIXENT $167 5 payments
  8. ADBRY $167 6 payments
  9. NUZYRA $159 3 payments
  10. SOTYKTU $156 8 payments
  11. Other $1,178 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

320

Median for Nurse Practitioner: 389

Drug cost

$10,798

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tacrolimus Generic 21 $4,338
Clobetasol Propionate Generic 82 $3,418
Ketoconazole Generic 56 $1,397
Fluconazole Generic 14 $616
Hydrocortisone Generic 47 $278
Dutasteride Generic 12 $220
Doxycycline Hyclate Generic 20 $157
Triamcinolone Acetonide Generic 29 $139
Finasteride Generic 11 $114
Terbinafine Hcl Generic 11 $65

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$99,911

Of which drugs: $53,259

Medicare patients

213

Average age 73

Services billed

1,890

132 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 29%
Diabetes 28%
Depression 26%
Chronic kidney disease 22%
Atrial fibrillation 15%
Osteoporosis 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 16 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $165
$165 — —
SILIQ
  • Ortho Dermatologics, a division of Bausch Health US, LLC $161
$161 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $131
$131 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $116
$116 — —
DUPIXENT
  • GENZYME CORPORATION $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record